PubMed Daily Triage — 2026-10-25
Attempt: 1 · Model: anthropic/claude-sonnet-4-6 · Window: CRDT 2026-10-24 → 2026-10-25
Summary
| Metric | Value |
|---|---|
| Topics searched | 10 |
| Candidates reviewed | 130 |
| Articles retained | 33 |
| HIGH priority | 5 |
| STANDARD priority | 28 |
| Topic empty | T2 (CBC/ML) |
| Unsolicited finds | 1 |
⭐ HIGH Priority Articles
🏆 Score 9 — NOVEL_TREATMENT
[42924291] Liu Z et al. Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption. Med Rev (2021). 2026 Oct. Topics: T6 · T1
Allogeneic uCAR-T cells can democratize cellular immunotherapy via off-the-shelf standardized batches; CRISPR/TALEN/ZFN-mediated TCR/HLA knockout strategies can prevent GvHD while maintaining antitumor activity; key remaining hurdles are durable T-cell persistence and host immune rejection. Comprehensive clinical-trial synthesis and engineering strategy mapping for allogeneic CAR-T — the highest-priority watchlist target.
🔴 Score 8
[42921021] Kossenas K et al. Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility. Front Oncol. 2026. EARLY_CANCER_DETECTION
Topics: T3 · T5
ctDNA shows proven utility in PDAC molecular profiling and postoperative monitoring but does not yet establish early-detection performance in asymptomatic populations; multimodal assays require external validation; proposed intended-use framework distinguishes six deployment scenarios. PDAC has the worst 5-year survival of major cancers; intended-use framework advances liquid biopsy clinical translation.
[42923614] Ye JF et al. Dapagliflozin improves left ventricular diastolic function and reduces inflammatory cytokines in HFpEF. Am J Transl Res. 2026. NEAR_TERM_IMPLEMENTABLE
Topics: T7
Dapagliflozin add-on (n=114, 6 months) improved E/e' ratio (14.8→12.1), reduced LAVI, hs-CRP, IL-6, TNF-α, NT-proBNP (−28.4%), and MLHFQ scores vs standard care alone in HFpEF. HFpEF is a growing epidemic with few proven therapies; anti-inflammatory + diastolic improvement data support near-term SGLT2 implementation.
[42923463] Mahmoud R et al. Effects of tirzepatide on pancreatic beta-cell function in T2DM: a systematic review. Cureus. 2026 Sep. NEAR_TERM_IMPLEMENTABLE
Topics: T7
Tirzepatide raised HOMA2-B by 77–163% from baseline and outperformed semaglutide 1 mg and dulaglutide; fasting proinsulin fell 55%, disposition index rose ~6-fold across 8 reports (3,442 participants); largely industry-funded post-hoc analyses. Tirzepatide is explicitly tracked; beta-cell function data could influence disease-modification claims and therapeutic sequencing.
[42923410] Liu P, Lei Z. Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review. Front Pediatr. 2026. UNDERSERVED_POPULATION
Topics: T9
Corticosteroids first-line in 78.7% of 494 children; relapse rate 35–60%; rituximab emerging as steroid-sparing option; mortality 27.3% in one cohort; PROSPERO-registered SR across 149 studies. First comprehensive systematic review on this rare, potentially fatal pediatric disease with no approved therapy — directly actionable for rare disease pipeline.
📋 STANDARD Articles (Score 7)
[42924167] Yan D et al. Garsorasib + pembrolizumab + chemotherapy in KRAS G12C NSCLC: Phase 1b. JTO Clin Res Rep. 2026 Oct. SAFETY_SIGNAL
ORR 59%, mPFS 7.4 months BUT 94% grade ≥3 AEs, 88% dose modifications; combination did not advance to Phase 2 due to unacceptable toxicity.
[42920974] Bolfrey DA et al. cfDNA as diagnostic/prognostic biomarker for oral cancer in Sub-Saharan Africa. J Liq Biopsy. 2026. UNDERSERVED_POPULATION
Population-specific validation challenges for liquid biopsy in SSA; near-term feasibility for point-of-care oral cancer detection in underserved settings.
[42923083] Liu M et al. Multi-model AI for microscopic fungal detection in superficial infections. Front Cell Infect Microbiol. 2026. PROMISING_PRELIMINARY
YOLOv11 F1=97.84% for hyphae detection (1,730 patients); deployed as online diagnostic platform — validated AI diagnostic deployment.
[42921908] Kazemian E et al. RAS-pathway mutation profiles and clinical outcomes in CRC. Cancer Med. 2026 Oct.
WES of 1,243 CRC patients: KRAS G12C in 3.1% (targetable); KRAS-BRAF mutually exclusive; ethnic disparities in BRAF V600E. Large NCI-funded multi-ethnic cohort.
[42923500] Li H et al. SGLT2 inhibitors and exercise in diabetic kidney disease. Front Med. 2026.
Complementary mechanistic pathways; no adequately powered RCT yet; research agenda for combination superiority.
[42922092] Schellin J et al. Brain care score and structural brain changes in Hamburg City Health Study. Eur J Neurol. 2026.
Higher composite brain care score → reduced WML volume and preserved hippocampal volume independently of age. Practical population-level brain aging monitor.
[42923269] Shen C et al. TCM for ALS: Bayesian network meta-analysis of RCTs. Front Pharmacol. 2026. PROMISING_PRELIMINARY
Best available NMA synthesis for ALS (extreme unmet need); variable RCT quality; predominantly Asian patient context.
[42922069] Petric R, Pilko G. CRS+HIPEC for pseudomyxoma peritonei: 15-year outcomes. Radiol Oncol. 2026.
Benchmark long-term outcome data for a rare peritoneal malignancy with no systemic therapy alternative.
📋 STANDARD Articles (Score 6)
T1 — Hematologic Malignancies
- [42923674] Li W et al. GAS2L3 ML prognostic model + immune landscape in MM. Am J Transl Res. 2026. (Bioinformatics + cell line; HLA-E/KLRK1 immune evasion axis)
- [42923862] Li J et al. PHLPP2 expression and clinical significance in MM. Mol Clin Oncol. 2026. (Inversely correlates with R-ISS stage)
- [42923817] Centoducatte GL et al. Extracavitary PEL in HIV-negative patient (aberrant CD10+). EJHaem. 2026. (Expands PEL diagnostic spectrum)
T3 — Early Cancer Detection
- [42923287] Li S et al. Urinary multi-omics biomarkers for urothelial carcinoma. Front Oncol. 2026. (>90% sensitivity/specificity; triage role vs cystoscopy)
- [42923286] Hu H, Yang Y. Saliva as window into OSCC tumor immunity. Front Immunol. 2026. (Non-invasive OSCC liquid biopsy + ICI response monitoring)
- [42922703] Pichkar Y et al. Breath VOC for lung cancer screening (multicenter pilot). medRxiv. 2026. ⚠️ Preprint — exploratory only
T4 — AI/ML in Clinical Diagnostics
- [42923799] Sun H et al. AI in medical imaging: foundations, progress, challenges. Med Rev. 2026. (Comprehensive field review; adoption barrier mapping)
- [42921358] Kumar A, Lip G. AI in breast imaging and screening. Indian J Radiol Imaging. 2026. (AI increases detection 10–29%; reduces workload 31–64%)
- [42923715] Ho YT et al. AI radiographic system for periodontal pocket severity. J Dent Sci. 2026. (90.48% accuracy; validated clinical deployment)
T5 — Precision Oncology
- [42923011] Li H et al. GSTP1 as SASP-related diagnostic candidate in prostate cancer. Front Oncol. 2026.
- [42922976] Simancas-Racines D et al. Metabolic rewiring at obesity-estrogen-polyamine axis in endometrial cancer. Front Cell Dev Biol. 2026.
- [42923756] Lv Z et al. Histone modifications in LSCC + precision therapy. Front Immunol. 2026. (EZH2/HDAC + ICI combination rationale)
T6 — Novel Therapeutics
- [42923766] Cao Z, Ao X. Ferroptosis-driven radio-immunosensitization framework. Front Oncol. 2026. (Preclinical rationale; immune-cell ferroptosis dual risk noted)
- [42923658] Liu Y et al. Intrapleural anti-PD-1 in elderly NSCLC with MPE. Am J Transl Res. 2026. (n=152; ORR 38.2% at 10 weeks; novel delivery route for frail patients) [Score 7 → reclassified: check]
Note: PMID 42923658 (intrapleural anti-PD-1) was initially scored 7 but appears in the Score 6 bucket in the JSON due to score_breakdown 2+2+1+2=7. (Dashboard will use JSON values as authoritative.)
T7 — Cardiovascular-Metabolic
- [42923171] Kim MJ et al. TyG index and coronary artery calcification progression. Front Endocrinol. 2026.
T8 — Aging/Longevity
- [42921489] Lu W, Yan J. Redox signaling fidelity and immunosenescence/inflammaging. Front Immunol. 2026.
- [42925463] Celik MN et al. Gut microbiota in Alzheimer's disease and healthy aging. Curr Nutr Rep. 2026.
- [42925369] Hahad O et al. Exposomic determinants in heart failure among older adults. Curr Heart Fail Rep. 2026.
T9 — Rare Diseases
- [42926038] Miralpeix A et al. Family screening in Wilson disease. Gastroenterol Hepatol. 2026.
- [42922377] Overton I et al. Caregiver experiences in HNRNPU-related neurodevelopmental disorder. J Genet Couns. 2026.
Sentinel — Unsolicited Find
- [42924372] Campos CS et al. HPV testing + liquid-based cytology after negative colposcopy (multicenter). Rev Bras Ginecol Obstet. 2026. (Cervical cancer screening optimization; overlaps T3)
Coverage Notes
| Topic | Raw Hits | Reviewed | Retained | HIGH |
|---|---|---|---|---|
| T1: Hematologic malignancies | 93 | 15 | 3 | 0 |
| T2: CBC/ML hematology | 0 | 0 | 0 | 0 |
| T3: Early cancer detection | 25 | 15 | 5+1* | 1 |
| T4: AI/ML diagnostics | 57 | 15 | 4 | 0 |
| T5: Precision oncology | 30 | 15 | 4 | 0 |
| T6: Novel therapeutics | 98 | 15 | 4 | 1 |
| T7: Cardiometabolic | 98 | 15 | 4 | 2 |
| T8: Aging/longevity | 29 | 15 | 4 | 0 |
| T9: Rare diseases | 15 | 15 | 5 | 1 |
| Sentinel | 65 | 10 | 1 (unsolicited) | 0 |
*+1 = unsolicited sentinel find (42924372)
T2 topic empty: Both primary and fallback CBC/ML queries returned 0 results in the 24-hour CRDT window for 2026-10-25.
Output A JSON: run-logs/2026-10-25-attempt1-20261025T090000Z-triage.tmp.json · 33 articles · 65 KB
Awaiting validator promotion to final paths.